# US 2020/0268939 A1 · Biomaterial comprising adipose-derived stem cells and method for producing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0268939 A1
- Document ID: US20200268939A1
- Status: Published application
- Kind: A1
- Application number: 16/646,755
- Filed: 2018-09-20
- Published: 2020-08-27
- Earliest claimed: 2017-09-20
- Assignees: Novadip Biosciences
- Applicants: Novadip Biosciences
- Inventors: Denis DUFRANE
- Web page: https://patentgrep.com/patent/US20200268939A1

## CPC

- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/365: {Bones}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/185: Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- C12N 2533/14: Ceramic
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α). The present invention also relates to methods for producing the biomaterial and uses thereof.

## Claims

### Claim 1

Biomaterial having a multi-dimensional structure comprising osteogenic differentiated adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix, wherein the biomaterial secretes osteoprotegerin (OPG) and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1α).

### Claim 2 (depends on 1)

The biomaterial according to claim 1, wherein the biomaterial secretes at least about 5 ng of OPG per g of biomaterial, preferably at least about 10 ng/g.

### Claim 3 (depends on 1)

The biomaterial according to claim 1, wherein the biomaterial comprises at least about 50 ng of IGF1 per g of biomaterial, preferably at least 75 ng.

### Claim 4 (depends on 1)

The biomaterial according to claim 1, wherein the biomaterial comprises at most about 100 ng of SDF-1α per g of biomaterial, preferably at most 75 ng.

### Claim 5 (depends on 1)

The biomaterial according to claim 1, wherein the ceramic material is in form of particles.

### Claim 6 (depends on 1)

The biomaterial according to claim 1, wherein the ceramic material is particles of calcium phosphate.

### Claim 7 (depends on 6)

The biomaterial according to claim 6, wherein the particles of calcium phosphate have an average size ranging from about 50 μm to about 1500 μm.

### Claim 8 (depends on 6)

The biomaterial according to claim 6, wherein the particles of calcium phosphate are particles of hydroxyapatite (HA) and/or β-tricalcium phosphate (β-TCP).

### Claim 9 (depends on 6)

The biomaterial according to claim 6, wherein the particles of calcium phosphate are particles of HA/13-TCP in a ratio ranging from 10/90 to 90/10, preferably from 20/80 to 80/20.

### Claim 10 (depends on 1)

The biomaterial according to claim 1, wherein the biomaterial comprises at least about 10 ng of VEGF per g of biomaterial.

### Claim 11 (depends on 1)

The biomaterial according to claim 1, wherein the biomaterial is three-dimensional.

### Claim 12 (depends on 1)

Medical device comprising the multi-dimensional biomaterial according to claim 1.

### Claim 13 (depends on 1)

Method for producing the multi-dimensional biomaterial according to claim 1 comprising the steps of:
adipose-derived stem cells (ASCs) proliferation,
ASCs osteogenic differentiation at the fourth passage, and
multi-dimensional induction, preferably 3D induction.

### Claim 14 (depends on 13)

A multi-dimensional biomaterial obtainable by the method according to claim 13.

### Claim 15 (depends on 1)

Biomaterial according to claim 1 for use for treating bone or cartilage defect.
